Contact

SPI is a small, founder-led organization, and your message reaches a real person. If your work touches any of the areas below, we'd like to hear from you — a short note about who you are and what you have in mind is plenty to start. When you're ready, use the message form below.

Researchers & clinical teams

This is the collaboration that matters most to the mission. If you study BPD, CPTSD, the endogenous opioid system, chronic suicidality, or self-harm — or you're weighing a pilot or trial of low-dose buprenorphine — we exist to lower your cost of starting. We can share a synthesized, citation-audited evidence base, a concept note for a stratified observational pilot, and a documented patient population that has opted in to being recruited.

Start a research conversation →

Ketamine clinics & clinician educators

Recent trial evidence suggests low-dose buprenorphine may extend ketamine's antisuicidal effect. SPI is developing honest, non-promotional training to help clinics understand that emerging evidence — what it does and doesn't yet support, and the clinical and regulatory care responsible use requires. If you run or advise a clinic and want to help shape or pilot that training, get in touch.

Talk to us about training →

Funders & grantmakers

SPI is an early-stage nonprofit building the research, clinical, and community case for treating social pain at its mechanism. If your priorities include mental health, suicide prevention, or the opioid-system science behind them, we're glad to share our theory of change and current plans.

Discuss funding →

Clinicians & prescribers

If you prescribe buprenorphine in other contexts and are considering its role in affective and interpersonal dysregulation, the prescriber guide is written for you. We can't offer clinical advice or answer questions about specific patients, but feedback on the guide, corrections, and case experience are welcome.

Share feedback or case experience →